Hikma Pharmaceuticals Plc (HIK) Receives Average Recommendation of “Hold” from Analysts

Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been assigned an average recommendation of “Hold” from the ten analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is GBX 1,088.89 ($15.04).

HIK has been the topic of several analyst reports. Numis Securities reaffirmed a “buy” rating and set a GBX 1,300 ($17.96) price target on shares of Hikma Pharmaceuticals in a research report on Wednesday, December 20th. Morgan Stanley reiterated an “equal weight” rating and issued a GBX 1,100 ($15.20) price objective on shares of Hikma Pharmaceuticals in a report on Friday, December 1st. Jefferies Group upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,045 ($14.44) to GBX 1,074 ($14.84) and gave the company a “hold” rating in a report on Monday, December 4th. Peel Hunt reiterated a “hold” rating and issued a GBX 1,390 ($19.20) price objective on shares of Hikma Pharmaceuticals in a report on Wednesday, November 15th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Hikma Pharmaceuticals from GBX 1,250 ($17.27) to GBX 1,000 ($13.82) and set a “neutral” rating on the stock in a report on Friday, November 10th.

How to Become a New Pot Stock Millionaire

Shares of Hikma Pharmaceuticals (HIK) opened at GBX 898.40 ($12.41) on Friday. Hikma Pharmaceuticals has a 1 year low of GBX 814.20 ($11.25) and a 1 year high of GBX 2,346 ($32.41). The stock has a market cap of $2,180.00 and a price-to-earnings ratio of 1,796.80.

COPYRIGHT VIOLATION WARNING: This story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/03/10/hikma-pharmaceuticals-plc-hik-receives-average-recommendation-of-hold-from-analysts.html.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply